Preview

Атеротромбоз

Расширенный поиск

НОВЫЕ АНТИКОАГУЛЯНТЫ: ПОВЫШЕНИЕ ЭФФЕКТИВНОСТИ ИЛИ СНИЖЕНИЕ БЕЗОПАСНОСТИ?

https://doi.org/10.21518/2307-1109-2013-1-38-43

Полный текст:

Аннотация

.

Об авторах

С. К. Зырянов
РНИМУ им. Н.И. Пирогова
Россия


Ю. Б. Белоусов
РНИМУ им. Н.И. Пирогова
Россия


Список литературы

1. Cohen A. T., Agnelli G., Anderson F. A., Arcelus J. I., Bergqvist D., Brecht J. G. etal. Venousthromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756–64.

2. Hirsh J., Raschke R. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S–203S.

3. Hochman J. S., Wali A. U., Barvila D. et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999; 138: 313– 8.

4. Hirsh J., Warkentin T. E., Raschke R., Granger C., Ohman E. M., Dalen J. E. Heparin and low-molecularweight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S–510S.

5. Geerts W. H., Bergqvist D., Pineo G. F., Heit J. A., Samama C. M., Lassen M. R. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133 (6 suppl): S381–453.

6. www.grls.rosminzdrav.ru

7. Diuguid D. L. Choosing a Paranteral Anticoagulant Agent. N Engl J Med 2001; 345:18, 1340–1341.

8. Панченко Е. П. Антикоагулянтная терапия в кардиологии: вчера, сегодня завтра. Кардиология. – 2010. – № 7. – С. 4–7.

9. Eriksson B. I., Dahl O. E., Rosencher N., Kurth A. A., van Dijk C. N., Frostick S. P. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J ThrombHaemost 2007; 5: 2178–85.

10. Eriksson B. I., Dahl O. E., Huo M. H., Kurth A. A., Hantel S., Hermansson K. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721–9.

11. Lassen M. R., Ageno W., Borris L. C., Lieberman J. R., Rosencher N Bandel T. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–86.

12. Turpie A. G., Lassen M. R., Davidson B. L., Bauer K. A., Gent M., Kwong L. M. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673–80.

13. Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., Hornick P. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized doubleblind trial. Lancet 2010; 375: 807–15.

14. Lassen M. R., Gallus A., Raskob G. E., Pineo G., Chen D., Ramirez L. M. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487–98.

15. Gomez-Outes A., Terleira-Fernandez A. I., Suarez- Gea L., Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for tromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344: e3675.

16. Yoshida R. de A., Yoshida W. B., Maffei R. et al. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. Annals of Vascular Surgery 2013; 27 (3): 355–369.

17. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17; 361 (12): 1139–51.

18. Uchino K., Hernandez A. V. Dabigatran Association with higher risk of acute coronary events. Metaanalysis of noninferiority randomized controlled trials. Arch Intern Med. Published online January 9, 2012. doi:10.1001/archinternmed. 2011. 1666.

19. Ezekowitz M. D., Reilly P. A., Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100 (9): 1419–1426.

20. Schulman S., Kearon C., Kakkar A. K. et al; RECOVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361 (24): 2342–2352.

21. Oldgren J., Budaj A., Granger C. B. et al. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32 (22): 2781–2789.

22. Eriksson B. I., Dahl O. E., Huo M. H. et al; RENOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105 (4): 721–729.

23. Eriksson B. I., Dahl O. E., Rosencher N. et al; RENOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370 (9591): 949–956.

24. Eriksson B. I., Dahl O. E., Rosencher N. et al; REMODEL Study Group. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5 (11): 2178–2185.

25. Albers G. W., Diener H. C., Frison L. et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005; 293 (6): 690–698.

26. Christersson C., Oldgren J., Wallentin L., Siegbahn A. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med. 2011; 270 (3): 215–223.

27. Connolly S. J., Eikelboom J., Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364 (9): 806–817.

28. Patel M. R., Mahaffey K. W., Garg J. et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 (10): 883–891.

29. Granger C. B., Alexander J. H., McMurray J. J. et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981–992. Medline: 21870978.


Для цитирования:


Зырянов С.К., Белоусов Ю.Б. НОВЫЕ АНТИКОАГУЛЯНТЫ: ПОВЫШЕНИЕ ЭФФЕКТИВНОСТИ ИЛИ СНИЖЕНИЕ БЕЗОПАСНОСТИ? Атеротромбоз. 2013;(1):38-43. https://doi.org/10.21518/2307-1109-2013-1-38-43

For citation:


Зырянов С.К., Белоусов Ю.Б. Atherothrombosis Journal. 2013;(1):38-43. (In Russ.) https://doi.org/10.21518/2307-1109-2013-1-38-43

Просмотров: 278


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)